The Effects of Two Types of Renin-angiotensin System Inhibitors on the Hypertension Induced by New Pressor Protein Associated with Beta-factor XIIa in Rats

Overview

Journal Res Pharm Sci

Specialty Chemistry

Date 2020 Jun 26

PMID 32582357

Authors

Akbar Pejhan

Ali Gohari

Mohammad Hassan Rakhshani

Peter C Papageorgiou

Muhammad Ibrar Mustafa

Rahim Golmohammadi

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: New pressor protein (NPP) is a human plasma enzyme, which is structurally related to the beta-fragment of activated factor XII. The present study aimed to compare the effects of angiotensin converting enzyme inhibitors (captopril) and angiotensin type 1 receptor blocker (losartan) on the hypertension induced by NPP injection in normal (sham-2NX) and bilaterally nephrectomized rats (2NX).

Experimental Approach: In total, 60 male Wistar rats were sham operated or bilaterally nephrectomized under anesthesia. After 24 h of anesthesia with Inactin® (100 mg/kg), their systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) were measured before and after the intravenous administration of captopril, losartan, and NPP.

Findings / Results: In the sham-2NX group, after NPP injection, changes were observed in SBP (145.99 ± 3.6 mmHg), DBP (93.9 ± 3.87 mmHg), and HR (400.29 ± 12.78 bpm). In the captopril group, SBP and DBP had no significant changes, while HR increased significantly ( = 0.001). In the losartan group, SBP and DBP decreased ( = 0.001 and = 0.000, respectively), while HR had no significant changes. In the 2NX group, after NPP injection, changes were denoted in SBP (127.89 ± 9.03 mmHg), DBP (65.86 ± 5.69 mmHg), and HR (333.35 ± 11.47 bpm). In addition, captopril injection increased DBP ( = 0.016) and HR ( = 0.036) in response to NPP injection, while losartan injection had no significant effects in this regard.

Conclusion And Implications: It could be concluded that losartan could improve hypertension in normal rats, while captopril deteriorated hypertension in bilaterally nephrectomized rats in this hypertension model.

References

Pearl R, Papageorgiou P, Goldman M, Amfilochiadis A, Boomsma F, Rojkjaer R . Possible role of new pressor protein in hypertensive anephric hemodialysis patients. Pediatr Nephrol. 2003; 18(10):1025-31. DOI: 10.1007/s00467-003-1246-6. View

Amfilochiadis A, Papageorgiou P, Kogan N, Boomsma F, Osmond D . Role of bradykinin B2-receptor in the sympathoadrenal effects of 'new pressor protein' related to human blood coagulation factor XII fragment. J Hypertens. 2004; 22(6):1173-81. DOI: 10.1097/00004872-200406000-00019. View

Mullick A, Yeh S, Graham M, Engelhardt J, Prakash T, Crooke R . Blood Pressure Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of Hypertension and Kidney Injury. Hypertension. 2017; 70(3):566-576. DOI: 10.1161/HYPERTENSIONAHA.117.09755. View

Janahmadi Z, Nekooeian A, Mozafari M . Hydroalcoholic extract of Allium eriophyllum leaves attenuates cardiac impairment in rats with simultaneous type 2 diabetes and renal hypertension. Res Pharm Sci. 2015; 10(2):125-33. PMC: 4584451. View

Kmietowicz Z . ACE inhibitors are linked to increased lung cancer risk, study finds. BMJ. 2018; 363:k4471. DOI: 10.1136/bmj.k4471. View

Papageorgiou P, Yeo E, Backx P, Floras J . Activated plasma coagulation β-Factor XII-induced vasoconstriction in rats. Clin Sci (Lond). 2012; 122(12):581-90. PMC: 3294432. DOI: 10.1042/CS20110517. View

Papageorgiou P, Chan C, Yeo E, Backx P, Floras J . Coagulation factor XIIa-kinin-mediated contribution to hypertension of chronic kidney disease. J Hypertens. 2014; 32(7):1523-33. DOI: 10.1097/HJH.0000000000000192. View

Abbasi S, Yousefi G, Ansari A, Mohammadi-Samani S . Formulation and in vitro evaluation of a fast-disintegrating/sustained dual release bucoadhesive bilayer tablet of captopril for treatment of hypertension crises. Res Pharm Sci. 2016; 11(4):274-83. PMC: 5022375. DOI: 10.4103/1735-5362.189284. View

Simos D, Boomsma F, Osmond D . Human coagulation factor XII-related "new pressor protein": role of PACAP in its cardiovascular and sympathoadrenal effects. Can J Cardiol. 2002; 18(10):1093-103. View

10.

Li E, Heran B, Wright J . Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014; (8):CD009096. PMC: 6486121. DOI: 10.1002/14651858.CD009096.pub2. View

11.

Kearney P, Whelton M, Reynolds K, Muntner P, Whelton P, He J . Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365(9455):217-23. DOI: 10.1016/S0140-6736(05)17741-1. View

12.

Forouzanfar M, Alexander L, Anderson H, Bachman V, Biryukov S, Brauer M . Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(10010):2287-323. PMC: 4685753. DOI: 10.1016/S0140-6736(15)00128-2. View

13.

Hicks B, Filion K, Yin H, Sakr L, Udell J, Azoulay L . Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018; 363:k4209. PMC: 6199558. DOI: 10.1136/bmj.k4209. View

14.

Almeida L, Tofteng S, Madsen K, Jensen B . Role of the renin-angiotensin system in kidney development and programming of adult blood pressure. Clin Sci (Lond). 2020; 134(6):641-656. DOI: 10.1042/CS20190765. View

15.

. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 385(9963):117-71. PMC: 4340604. DOI: 10.1016/S0140-6736(14)61682-2. View

16.

Papageorgiou P, Simos D, Boomsma F, Rojkjaer R, Osmond D . Angiotensin converting enzyme-regulated, noncholinergic sympathoadrenal catecholamine release mediates the cardiovascular actions of human 'new pressor protein' related to coagulation beta-factor XIIa. Can J Cardiol. 2009; 25(4):e100-8. PMC: 2706768. DOI: 10.1016/s0828-282x(09)70067-4. View

17.

Messerli F, Bangalore S, Bavishi C, Rimoldi S . Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?. J Am Coll Cardiol. 2018; 71(13):1474-1482. DOI: 10.1016/j.jacc.2018.01.058. View

18.

Papageorgiou P, Pourdjabbar A, Amfilochiadis A, Diamandis E, Boomsma F, Osmond D . Are cardiovascular and sympathoadrenal effects of human "new pressor protein" preparations attributable to human coagulation beta-FXIIa?. Am J Physiol Heart Circ Physiol. 2003; 286(3):H837-46. DOI: 10.1152/ajpheart.00693.2003. View

19.

Aldehni F, Tang T, Madsen K, Plattner M, Schreiber A, Friis U . Stimulation of renin secretion by catecholamines is dependent on adenylyl cyclases 5 and 6. Hypertension. 2011; 57(3):460-8. PMC: 3106204. DOI: 10.1161/HYPERTENSIONAHA.110.167130. View